Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, reasonably pr